Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Paliperidone“
Suchtreffer
Begriffe & Kennungen
Byannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Potential for other medicines to affect BYANNLI
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · Since paliperidone is the major active metabolite of risperidone, caution should be exercised when BYANNLI is
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.5 · The combined use of psychostimulants (e.g. methylphenidate) with paliperidone can lead to extrapyramidal sympt
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 Undesirable effects · 1
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · 12 Nervous system parkinsonismc, tardive dyskinesia, neuroleptic diabetic coma disorders akathisiac, sedation/
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · 13 Renal and urinary urinary urinary retention disorders incontinence, pollakiuria, dysuria Pregnancy, drug wi
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · 14 EPS included a pooled analysis of the following terms: parkinsonism (includes extrapyramidal disorder, extr
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Anaphylactic reaction Rarely, cases of anaphylactic reaction after injection with 1-monthly paliperidone palmi
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Cases of VTE, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Changes in body weight In the 12-month clinical trial of BYANNLI, the number of subjects with abnormal weight
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Class effects
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Description of selected adverse reactions
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Extrapyramidal symptoms (EPS) In the clinical trial of BYANNLI, akathisia, dyskinesia, dystonia, parkinsonism,
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Hyperprolactinaemia In the 12-month clinical trial of BYANNLI, the mean (SD) change from double-blind baseline
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Injection site reactions In the clinical trial of BYANNLI, 10.7% of subjects reported injection site related a
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Number of patients with abnormal weight percent change from (double-blind) baseline to end point
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · PP3M1 BYANNLI Weight percent change (N=219) (N=473) Decrease ≥ 7% 15 (6.8%) 43 (9.1%) Increase ≥ 7% 29 (13.2%)
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · Paliperidone is the active metabolite of risperidone, therefore, the adverse reaction profiles of these compou
Eintrag öffnenByannli (previously Paliperidone Janssen-Cilag International) · 4.8 · QT prolongation, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), sudden unexplain
Eintrag öffnen